LEARNING OBJECTIVES:
At the conclusion of this activity, participants will be able to:
1. Identify appropriate use of genetic testing, genetic counseling as well as somatic testing.
2. Describe appropriate use of treatment-related to specific genetic alterations.
3. Identify appropriate combination therapy with ADT plus novel androgen receptor pathway inhibitors and chemotherapy. Early treatment intensification as well as appropriate de intensification will be discussed in mHSCPC.
4. Describe the treatments for non-metastatic CRPC and oncologic outcomes based on AUA/SUO and NCCN Guidelines.
5. Counsel patients on available treatment options for CRPC as well as combination therapy and sequencing based on AUA/SUO and NCCN Guidelines.
ACKNOWLEDGEMENTS:
Support provided by independent educational grants from:
Astellas
Lantheus Medical Imaging
Novartis Pharmaceuticals Corporation
Pfizer, Inc
Podden och tillhörande omslagsbild på den här sidan tillhör
American Urological Association. Innehållet i podden är skapat av American Urological Association och inte av,
eller tillsammans med, Poddtoppen.